Intro
Tecan Group is a Swiss laboratory automation specialist founded in 1980 by four engineers working out of a home office in Switzerland. Over the past four decades, the company has grown into a global leader in liquid handling, robotic workstations and detection instruments – the kind of equipment that pharma companies, diagnostic labs and university research departments rely on to process samples at scale. If you've had a blood test or a COVID PCR swab, there's a decent chance a Tecan-built machine was involved somewhere along the chain.
The company operates in two segments. Life Sciences Business sells instruments and consumables directly to end users. Partnering Business develops and manufactures OEM instruments and components that are then sold by diagnostic and medtech partners under their own brands.
The stock has dropped roughly 80% from its September 2021 peak of CHF 602, hammered by a post-pandemic destocking cycle, reduced pharma and biotech R&D spending, and a strong Swiss franc. Management just announced a transformation program called "Rewired" under new CEO Monica Manotas, who took the helm in August 2025.
Valuation
At CHF 121.60, Tecan's market cap is approximately CHF 1.55 billion. The headline numbers look ugly: a reported net loss of CHF 110.7 million in 2025, or CHF –8.74 per share. But that figure is distorted by a CHF 139.5 million non-cash impairment charge. Strip out that write-down and acquisition-related costs, and the adjusted earnings per share come in at CHF 6.87 – putting the stock at about 18x adjusted trough earnings.
Here's what makes this interesting from a balance sheet perspective: Tecan carries a net cash position of CHF 160.8 million. For a company generating CHF 138 million in operating cash flow per year with cash conversion running above 100% of EBITDA, that's a very comfortable setup. There is essentially no financial leverage to worry about.
In better years – 2022 and 2023 – Tecan earned around CHF 10 per share. Apply that kind of normalized earning power to today's share price and you're looking at a P/E in the range of 12–13x. Meanwhile, the dividend of CHF 3.00 per share – held steady through the downturn – yields about 2.5%, well covered by cash flow. On top of that, Tecan launched a share buyback program in August 2025 allowing for repurchases of up to CHF 120 million over two years – of which CHF 25 million had already been deployed by year-end.
What's next?
The near-term picture is not without risk. Life science spending remains soft, the Swiss franc continues to punish reported results, and potential new tariffs are adding another headwind. Management's 2026 guidance – low-single-digit local currency sales growth and an adjusted EBITDA margin of 15.5–16.5% – underwhelmed the market. The USD 1 billion Paramit acquisition, paid at the top of the cycle, has clearly not delivered what was hoped for, and the CHF 139.5 million impairment is management's admission of that.
But the underlying business is resilient. Tecan's instruments are embedded in customers' workflows – once installed, they generate recurring demand for consumables, software and service contracts. The medium-term target of CHF 1 billion in sales and a 20% adjusted EBITDA margin by 2028, if achieved, would imply a very different earnings profile from today's depressed figures.
A high-quality laboratory automation franchise with net cash, strong cash flow and deeply depressed earnings, trading at a fraction of its historical valuation – that's a setup patient investors tend to be rewarded for.
Current Price
CHF 121.60 per share
Disclosure
The author is currently long TECN.
No comments:
Post a Comment